Branded

CAMBRIDGE, Mass. — French drug maker Sanofi-Aventis will acquire U.S. biotech giant Genzyme for $20.1 billion, under an agreement the two companies announced Wednesday.

WASHINGTON — The National Association of Chain Drug Stores and its members from across the country once again are flocking to Capitol Hill for RxImpact Day, a groundbreaking, two-day event that enables pharmacists to meet with members of Congress to discuss the vital role of retail pharmacy within the U.S. healthcare system and its ability to help reduce annual healthcare costs.

NEW YORK — It shouldn’t surprise people too much, but pills to treat male impotence tend to see big increases in prescriptions around Valentine’s Day, according to published reports.

Bloomberg reported that prescriptions of such drugs as Pfizer’s Viagra (sildenafil) and Eli Lilly’s Cialis (tadalafil) are at their highest in the days leading up to the holiday.

MORRISTOWN, N.J. — Watson's global generics business drove the drug maker's net revenue in the fourth quarter, according to a financial earnings release.

PALATINE, Ill. — The Food and Drug Administration has accepted for review an application for a pain medication designed to thwart drug abusers.

Acura Pharmaceuticals announced Monday the acceptance of King Pharmaceuticals’ application for Acurox (oxycodone hydrochloride). King developed the drug using Acura’s Aversion technology, which is designed to limit or impede the ability to abuse the drug by dissolving or crushing the pills and then injecting them.

NEW YORK — An investigational drug made by Bristol-Myers Squibb works better than aspirin in reducing the risk of complications in certain patients with heart rhythm problems, according to results of a late-stage clinical trial published in the New England Journal of Medicine.

Bristol said results of the phase-3 study comparing apixaban with aspirin showed that in patients with atrial fibrillation who were not suited to take the drug warfarin, apixaban was more effective than aspirin in reducing stroke and systemic embolism.

INDIANAPOLIS — Following the exit of its oncology unit leader, drug maker Eli Lilly announced two executive changes.

Sue Mahony, currently SVP human resources and diversity, has been named SVP and president of Lilly Oncology, effective immediately. Mahony will remain a member of Lilly's executive committee. She succeeds John Johnson, who resigned from his post at Lilly last month to become CEO of Savient Pharmaceuticals.

PHILADELPHIA — GlaxoSmithKline has changed prescribing information on the labeling for one of its Type 2 diabetes drugs to reflect new restrictions on the drug’s use, the drug maker said.

GSK said it revised the labeling for Avandia (rosiglitazone) to take into account the risks of heart attacks and heart failure in patients taking the drug.

The FDA moved to restrict access to Avandia last year and required GSK to create a risk evaluation and mitigation strategy for the drug.